NCT07158450

Novel On-body Evaluation of Cardiac Health for Oncology

Enrolling by Invitation
Not specifiedAges 18+Observational
Skribe Medical
~500 participants
Updated 2026-05-20 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Correlation between wearable-derived and transthoracic echocardiography-derived left ventricular ejection fraction estimates
Measured over From baseline through study completion (up to 6 months) at each paired assessment
Cardiotoxicity
Heart Failure
7 sites across 7 states
Colorado1
Florida1
Illinois1
Louisiana1
New York1
Pennsylvania1
Tennessee1

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Undergoing an echocardiogram irrespective of participation in this study
Willing and able to provide informed consent prior to any study-related activity

Exclusion

Have a documented allergy to potential tissue contacting system materials
Have any condition that would cause inaccurate TTE measurements
  • Correlation between wearable-derived and transthoracic echocardiography-derived left ventricular ejection fraction estimatesFrom baseline through study completion (up to 6 months) at each paired assessment

    The primary analysis will compute the correlation coefficient (r) between wearable-derived model estimates of LVEF and transthoracic echocardiography-derived LVEF in the Hold-Out Test Set. The prespecified performance target is r \> 0.70.